Molecular Markers in Thyroid Cancer Diagnostics

Surgical Clinics of North America

Volumn 89, Issue 5, 2009, Pages 1139-1155

  Kato, Meredith A ^a   Fahey III, Thomas J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Galectin 3; HBME 1; Microarray; Thyroid cancer; Thyroid cancer diagnostics; Thyroid FNA

Indexed keywords

ANTIBODY; B RAF KINASE; CYTOKERATIN 19; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL CELL ANTIBODY; MICRORNA; MOLECULAR MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN PATCHED; PROTEIN RET; TELOMERASE; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ASPIRATION BIOPSY; CARCINOGENESIS; DIAGNOSTIC ACCURACY; GENE MUTATION; GENETIC MARKER; HUMAN; IMMUNOCYTOCHEMISTRY; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID NODULE;

BIOLOGICAL MARKERS; BIOPSY, FINE-NEEDLE; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; THYROID NEOPLASMS;

EID: 70349887754     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2009.06.012     Document Type: Review

References (144)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
2. Vander J.B., Gaston E.A., and Dawber T.R. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 69 3 (1968) 537-540
3. Wang C., and Crapo L.M. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 26 1 (1997) 189-218
4. Mazzaferri E.L. Management of a solitary thyroid nodule. N Engl J Med 328 8 (1993) 553-559
5. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 18 (2006) 2164-2167
6. Gharib H., and Goellner J.R. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 118 4 (1993) 282-289
7. Yang G.C., Liebeskind D., and Messina A.V. Ultrasound-guided fine-needle aspiration of the thyroid assessed by Ultrafast Papanicolaou stain: data from 1135 biopsies with a two- to six-year follow-up. Thyroid 11 6 (2001) 581-589
8. Yang J., Schnadig V., Logrono R., et al. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 111 5 (2007) 306-315
9. Baloch Z.W., Fleisher S., LiVolsi V.A., et al. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 26 1 (2002) 41-44
10. Yang G.C., Liebeskind D., and Messina A.V. Should cytopathologists stop reporting follicular neoplasms on fine-needle aspiration of the thyroid?. Cancer 99 2 (2003) 69-74
11. Stelow E.B., Bardales R.H., Crary G.S., et al. Interobserver variability in thyroid fine-needle aspiration interpretation of lesions showing predominantly colloid and follicular groups. Am J Clin Pathol 124 2 (2005) 239-244
12. Greaves T.S., Olvera M., Florentine B.D., et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer 90 6 (2000) 335-341
13. Liu F.T., and Rabinovich G.A. Galectins as modulators of tumour progression. Nat Rev Cancer 5 1 (2005) 29-41
14. Yoshii T., Inohara H., Takenaka Y., et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18 4 (2001) 787-792
15. Takenaka Y., Inohara H., Yoshii T., et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 195 1 (2003) 111-119
16. Xu X.C., el-Naggar A.K., and Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147 3 (1995) 815-822
17. Inohara H., Honjo Y., Yoshii T., et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85 11 (1999) 2475-2484
18. Fernandez P.L., Merino M.J., Gomez M., et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 181 1 (1997) 80-86
19. Orlandi F., Saggiorato E., Pivano G., et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58 14 (1998) 3015-3020
20. Giannini R., Faviana P., Cavinato T., et al. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 13 8 (2003) 765-770
21. Saussez S., Glinoer D., Chantrain G., et al. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18 7 (2008) 705-712
22. Inohara H., Segawa T., Miyauchi A., et al. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun 376 3 (2008) 605-610
23. Bartolazzi A., Orlandi F., Saggiorato E., et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 9 6 (2008) 543-549
24. Collet J.F., Hurbain I., Prengel C., et al. Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer 93 10 (2005) 1175-1181
25. Rossi E.D., Raffaelli M., Minimo C., et al. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer 105 2 (2005) 87-95
26. Saggiorato E., De Pompa R., Volante M., et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12 2 (2005) 305-317
27. Kim M.J., Kim H.J., Hong S.J., et al. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol 50 1 (2006) 28-34
28. Mehrotra P., Okpokam A., Bouhaidar R., et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45 5 (2004) 493-500
29. Bartolazzi A., and Bussolati G. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 48 2 (2006) 212-213
30. Sanabria A., Carvalho A.L., Piana de Andrade V., et al. Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence. Head Neck 29 11 (2007) 1046-1054
31. Sheibani K., Esteban J.M., Bailey A., et al. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 23 2 (1992) 107-116
32. Sack M.J., Astengo-Osuna C., Lin B.T., et al. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10 7 (1997) 668-674
33. de Micco C., Savchenko V., Giorgi R., et al. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer 98 4 (2008) 818-823
34. van Hoeven K.H., and Kovatich A.J. Immunohistochemical staining for proliferating cell nuclear antigen, BCL2, and Ki-67 in vulvar tissues. Int J Gynecol Pathol 15 1 (1996) 10-16
35. Wiseman S.M., Melck A., Masoudi H., et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 15 10 (2008) 2811-2826
36. Rossi E.D., Raffaelli M., Mule A., et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48 7 (2006) 795-800
37. Scognamiglio T., Hyjek E., Kao J., et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126 5 (2006) 700-708
38. Nga M.E., Lim G.S., Soh C.H., et al. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 36 8 (2008) 550-556
39. Kirkpatrick K.L., and Mokbel K. The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur J Surg Oncol 27 8 (2001) 754-760
40. Brousset P., Chaouche N., Leprat F., et al. Telomerase activity in human thyroid carcinomas originating from the follicular cells. J Clin Endocrinol Metab 82 12 (1997) 4214-4216
41. Umbricht C.B., Saji M., Westra W.H., et al. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 57 11 (1997) 2144-2147
42. Kammori M., Takubo K., Nakamura K., et al. Telomerase activity and telomere length in benign and malignant human thyroid tissues. Cancer Lett 159 2 (2000) 175-181
43. Saji M., Westra W.H., Chen H., et al. Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid. Surgery 122 6 (1997) 1137-1140
44. Yashima K., Vuitch F., Gazdar A.F., et al. Telomerase activity in benign and malignant thyroid diseases. Surgery 122 6 (1997) 1141-1145 [discussion: 5-6]
45. Bornstein-Quevedo L., Garcia-Hernandez M.L., Camacho-Arroyo I., et al. Telomerase activity in well-differentiated papillary thyroid carcinoma correlates with advanced clinical stage of the disease. Endocr Pathol 14 3 (2003) 213-219
46. Cheng A.J., Lin J.D., Chang T., et al. Telomerase activity in benign and malignant human thyroid tissues. Br J Cancer 77 12 (1998) 2177-2180
47. Onoda N., Ishikawa T., Yoshikawa K., et al. Telomerase activity in thyroid tumors. Oncol Rep 5 6 (1998) 1447-1450
48. Haugen B.R., Nawaz S., Markham N., et al. Telomerase activity in benign and malignant thyroid tumors. Thyroid 7 3 (1997) 337-342
49. Okayasu I., Osakabe T., Fujiwara M., et al. Significant correlation of telomerase activity in thyroid papillary carcinomas with cell differentiation, proliferation and extrathyroidal extension. Jpn J Cancer Res 88 10 (1997) 965-970
50. Trulsson L.M., Velin A.K., Herder A., et al. Telomerase activity in surgical specimens and fine-needle aspiration biopsies from hyperplastic and neoplastic human thyroid tissues. Am J Surg 186 1 (2003) 83-88
51. Straight A.M., Patel A., Fenton C., et al. Thyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents. J Endocrinol Invest 25 4 (2002) 302-308
52. Lo C.Y., Lam K.Y., Chan K.T., et al. Telomerase activity in thyroid malignancy. Thyroid 9 12 (1999) 1215-1220
53. Ito Y., Yoshida H., Tomoda C., et al. Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer Res 25 1B (2005) 509-514
54. Asaad N.Y., Abd El-Wahed M.M., and Mohammed A.G. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma: diagnostic and prognostic role. J Egypt Natl Canc Inst 18 1 (2006) 8-16
55. Saji M., Xydas S., Westra W.H., et al. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 5 6 (1999) 1483-1489
56. Hoang-Vu C., Boltze C., Gimm O., et al. Expression of telomerase genes in thyroid carcinoma. Int J Oncol 21 2 (2002) 265-272
57. Wang Y., Kowalski J., Tsai H.L., et al. Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid 18 10 (2008) 1055-1063
58. Mora J., and Lerma E. Telomerase activity in thyroid fine needle aspirates. Acta Cytol 48 6 (2004) 818-824
59. Kammori M., Nakamura K., Hashimoto M., et al. Clinical application of human telomerase reverse transcriptase gene expression in thyroid follicular tumors by fine-needle aspirations using in situ hybridization. Int J Oncol 22 5 (2003) 985-991
60. Liou M.J., Chan E.C., Lin J.D., et al. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett 191 2 (2003) 223-227
61. Matthews P., Jones C.J., Skinner J., et al. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol 194 2 (2001) 183-193
62. Sebesta J., Brown T., Williard W., et al. Does telomerase activity add to the value of fine needle aspirations in evaluating thyroid nodules?. Am J Surg 181 5 (2001) 420-422
63. Lerma E., and Mora J. Telomerase activity in "suspicious" thyroid cytology. Cancer 105 6 (2005) 492-497
64. Guerra L.N., Miler E.A., Moiguer S., et al. Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma. Clin Chim Acta 370 1-2 (2006) 180-184
65. Fagin J.A., and Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22 6 (2008) 955-969
66. Peyssonnaux C., and Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93 1-2 (2001) 53-62
67. Dhillon A.S., and Kolch W. Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 5 4 (2004) 303-304
68. Kimura E.T., Nikiforova M.N., Zhu Z., et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 7 (2003) 1454-1457
69. Cohen Y., Xing M., Mambo E., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95 8 (2003) 625-627
70. Cohen Y., Rosenbaum E., Clark D.P., et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10 8 (2004) 2761-2765
71. Fugazzola L., Mannavola D., Cirello V., et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61 2 (2004) 239-243
72. Knauf J.A., Ma X., Smith E.P., et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65 10 (2005) 4238-4245
73. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 11 (2003) 5399-5404
74. Kim T.Y., Kim W.B., Rhee Y.S., et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65 3 (2006) 364-368
75. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 12 (2005) 6373-6379
76. Pizzolanti G., Russo L., Richiusa P., et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 17 11 (2007) 1109-1115
77. Jo Y.S., Huang S., Kim Y.J., et al. Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf) 70 1 (2009) 139-144
78. Jin L., Sebo T.J., Nakamura N., et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 15 3 (2006) 136-143
79. Chung K.W., Yang S.K., Lee G.K., et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65 5 (2006) 660-666
80. Salvatore G., Giannini R., Faviana P., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89 10 (2004) 5175-5180
81. Xing M., Tufano R.P., Tufaro A.P., et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89 6 (2004) 2867-2872
82. Kim S.K., Kim D.L., Han H.S., et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17 2 (2008) 118-125
83. Rowe L.R., Bentz B.G., and Bentz J.S. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 3 (2006) 10
84. Domingues R., Mendonca E., Sobrinho L., et al. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 16 1 (2005) 27-31
85. Sapio M.R., Posca D., Raggioli A., et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66 5 (2007) 678-683
86. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21 Suppl 2 (2008) S37-S43
87. Santoro M., Carlomagno F., Hay I.D., et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89 5 (1992) 1517-1522
88. Adeniran A.J., Zhu Z., Gandhi M., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30 2 (2006) 216-222
89. Jhiang S.M., Caruso D.R., Gilmore E., et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 7 7 (1992) 1331-1337
90. Santoro M., Chiappetta G., Cerrato A., et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12 8 (1996) 1821-1826
91. Jhiang S.M., Sagartz J.E., Tong Q., et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137 1 (1996) 375-378
92. Powell Jr. D.J., Russell J., Nibu K., et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 58 23 (1998) 5523-5528
93. Nikiforov Y.E., Rowland J.M., Bove K.E., et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57 9 (1997) 1690-1694
94. Hamatani K., Eguchi H., Ito R., et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 68 17 (2008) 7176-7182
95. Ito T., Seyama T., Iwamoto K.S., et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 53 13 (1993) 2940-2943
96. Mizuno T., Kyoizumi S., Suzuki T., et al. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 15 12 (1997) 1455-1460
97. Cheung C.C., Carydis B., Ezzat S., et al. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86 5 (2001) 2187-2190
98. Elisei R., Romei C., Vorontsova T., et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 86 7 (2001) 3211-3216
99. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289 5483 (2000) 1357-1360
100. Dwight T., Thoppe S.R., Foukakis T., et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88 9 (2003) 4440-4445
101. Nikiforova M.N., Biddinger P.W., Caudill C.M., et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26 8 (2002) 1016-1023
102. Cheung L., Messina M., Gill A., et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88 1 (2003) 354-357
103. Marques A.R., Espadinha C., Catarino A.L., et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87 8 (2002) 3947-3952
104. Hibi Y., Nagaya T., Kambe F., et al. Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA?. Endocr J 51 3 (2004) 361-366
105. Sahin M., Allard B.L., Yates M., et al. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 90 1 (2005) 463-468
106. Nikiforova M.N., Lynch R.A., Biddinger P.W., et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88 5 (2003) 2318-2326
107. Gregory Powell J., Wang X., Allard B.L., et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 23 20 (2004) 3634-3641
108. Au A.Y., McBride C., Wilhelm Jr. K.G., et al. PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 147 1 (2006) 367-376
109. Marques A.R., Espadinha C., Frias M.J., et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91 4 (2004) 732-738
110. Lacroix L., Lazar V., Michiels S., et al. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167 1 (2005) 223-231
111. Lui W.O., Foukakis T., Liden J., et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene. Oncogene 24 8 (2005) 1467-1476
112. Giordano T.J., Au A.Y., Kuick R., et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 12 7 Pt 1 (2006) 1983-1993
113. Nikiforova M.N., Tseng G.C., Steward D., et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93 5 (2008) 1600-1608
114. Pallante P., Visone R., Ferracin M., et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13 2 (2006) 497-508
115. Chen Y.T., Kitabayashi N., Zhou X.K., et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 21 9 (2008) 1139-1146
116. Visone R., Russo L., Pallante P., et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 14 3 (2007) 791-798
117. Weber F., Teresi R.E., Broelsch C.E., et al. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 91 9 (2006) 3584-3591
118. Visone R., Pallante P., Vecchione A., et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26 54 (2007) 7590-7595
119. Finley D.J., Lubitz C.C., Wei C., et al. Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid 15 6 (2005) 562-568
120. Lubitz C.C., Gallagher L.A., Finley D.J., et al. Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138 6 (2005) 1042-1048 [discussion: 8-9]
121. Barden C.B., Shister K.W., Zhu B., et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9 5 (2003) 1792-1800
122. Finley D.J., Arora N., Zhu B., et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89 7 (2004) 3214-3223
123. Finley D.J., Zhu B., and Fahey III T.J. Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 136 6 (2004) 1160-1168
124. Finley D.J., Zhu B., Barden C.B., et al. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240 3 (2004) 425-436 [discussion: 36-7]
125. Lubitz C.C., Ugras S.K., Kazam J.J., et al. Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8 4 (2006) 490-498 quiz 528
126. Weber F., Shen L., Aldred M.A., et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 90 5 (2005) 2512-2521
127. Mazzanti C., Zeiger M.A., Costouros N.G., et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64 8 (2004) 2898-2903
128. Prasad N.B., Somervell H., Tufano R.P., et al. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res 14 11 (2008) 3327-3337
129. Fujarewicz K., Jarzab M., Eszlinger M., et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer 14 3 (2007) 809-826
130. Jarzab B., Wiench M., Fujarewicz K., et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65 4 (2005) 1587-1597
131. Fontaine J.F., Mirebeau-Prunier D., Franc B., et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene 27 15 (2008) 2228-2236
132. Aldred M.A., Huang Y., Liyanarachchi S., et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22 17 (2004) 3531-3539
133. Yano Y., Uematsu N., Yashiro T., et al. Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10 6 (2004) 2035-2043
134. Yukinawa N., Oba S., Kato K., et al. A multi-class predictor based on a probabilistic model: application to gene expression profiling-based diagnosis of thyroid tumors. BMC Genomics 7 (2006) 190
135. Rosen J., He M., Umbricht C., et al. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery 138 6 (2005) 1050-1056 [discussion: 6-7]
136. Foukakis T., Gusnanto A., Au A.Y., et al. A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer 14 2 (2007) 381-391
137. Denning K.M., Smyth P.C., Cahill S.F., et al. A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. Mod Pathol 20 10 (2007) 1095-1102
138. Cerutti J.M., Delcelo R., Amadei M.J., et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113 8 (2004) 1234-1242
139. Pagedar N.A., Chen D.H., Wasman J.K., et al. Molecular classification of thyroid nodules by cytology. Laryngoscope 118 4 (2008) 692-696
140. Shibru D., Hwang J., Khanafshar E., et al. Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?. Cancer 113 5 (2008) 930-935
141. Kebebew E., Peng M., Reiff E., et al. Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. World J Surg 30 5 (2006) 767-774
142. Kebebew E., Peng M., Reiff E., et al. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg 242 3 (2005) 353-361 [discussion: 61-3]
143. Kebebew E., Peng M., Reiff E., et al. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery 138 6 (2005) 1102-1109 [discussion: 9-10]
144. Kebebew E., Peng M., Reiff E., et al. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106 12 (2006) 2592-2597